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Abstract: Angiogenesis has a clear and deﬁ  nite role in the breast cancer progression process, 
making antivascular endothelial growth factor (VEGF) therapies an attractive option for the 
treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal 
antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical 
setting, either alone or in combination with cytotoxic treatment. Additionally, bevacizumab 
potentially increases the effectiveness of other anticancer therapies through the normalization 
of tumor vasculature, reduction of intratumoral pressure and improved tumor oxygenation. 
Phase 1/2 trials showed signiﬁ  cant antitumor effects of bevacizumab in MBC, in particular in 
tumors not expressing HER2 receptor. A ﬁ  rst phase 3 trial in pre-treated MBC patients showed 
better response rates but no survival beneﬁ  t from the addition of bevacizumab to capecitabine. 
However, in two phase 2 trial in ﬁ  rst-line setting in patients with MBC, bevacizumab improved 
progression-free survival in combination with weekly paclitaxel in comparison to paclitaxel alone 
or in combination with 3-weekly docetaxel in comparison with docetaxel alone, respectively. 
Bevacizumab in combination with taxanes seems to be a highly effective ﬁ  rst-line treatment 
for MBC patients. Future research will investigate bevacizumab in the neoadjuvant or adjuvant 
setting, where even more potential may exist for these patients.
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Introduction
Breast cancer represents a heterogeneous array of different disease subtypes with 
unique molecular phenotypes and distinct clinical features (Slamon et al 2006). 
Despite advances in the treatment of early-stage breast cancer, approximately one 
third of patients will eventually develop metastatic breast cancer (MBC) (Early Breast 
Cancer Trialists’ Collaborative Group 1998). The prognosis of patients with MBC is 
poor, with a median survival time ranging from 24 to 48 months (Gennari et al 2005). 
Recently, advances in understanding the biology of breast cancer have led to the 
classiﬁ  cation of breast tumors based upon their molecular features and the advent of 
targeted therapies for the treatment of both early and MBC. Targeted agents and their 
promise of better patient outcome with respect to safety, survival, and quality of life 
may change the clinical course for many MBC patients. Vascular endothelial growth 
factor (VEGF) is a critical mediator in tumor angiogenesis for many solid malignan-
cies, including breast cancer (Ferrara et al 1997). Upon binding to its receptor, VEGF 
induces a cascade of intracellular signals inducing cellular proliferation, increased 
vaso-permeability, inhibition of apoptosis, and ultimately angiogenesis. For many 
tumors, VEGF appears to be a rate-limiting signal in angiogenesis, making it an 
attractive target for therapeutic agents. Bevacizumab is a humanized recombinant 
antibody that prevents VEGF receptor binding, and inhibits angiogenesis and tumor 
growth (Manley et al 2002). Its use has been recently approved in the US and in the Biologics: Targets & Therapy 2008:2(4) 814
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EU for colorectal cancer, breast cancer, non-small cell lung 
cancer, and renal cell carcinoma (Genentech Inc., European 
Medicines Agency).
Preclinical data
Preclinical data suggested the potential for synergy by 
combining targeted antiangiogenic agents with traditional 
cytotoxic chemotherapy (Kakeji et al 1997; Gasparini et al 
2005). Anti-VEGF therapies may help to “normalize” the 
chaotic architecture of vessels within tumors, reducing 
vascular permeability and interstitial ﬂ  uid pressure, and 
potentially improving cytotoxic drug delivery (Jain 2005). 
In murine breast cancer models, twice-weekly intraperi-
toneal administration of A.4.6.1 (an antibody parent to 
bevacizumab), at a dose of 200 μg, signiﬁ  cantly suppressed 
angiogenic activity (Borgstrom et al 1999). Doxorubicin 
alone also reduced the growth rate of MCF-7 cells but did 
not affect angiogenesis signiﬁ  cantly. In contrast, doxorubicin 
with A.4.6.1 signiﬁ  cantly reduced tumor regression, so that 
viable tumor cells could not be detected in some animals 
at the end of the 2-week observation period. In another 
trial, endothelial-cell stimulation with VEGF and bFGF 
protected endothelial cells from the antiangiogenic proper-
ties of docetaxel, but protection was lost when bevacizumab 
was co-administered with docetaxel, both in vitro and in 
vivo (Sweeney et al 2001). These data strongly support the 
view that neutralization of VEGF with bevacizumab, in 
combination with conventional cytotoxic agents, could be a 
promising treatment for MBC.
Phase 1 and early phase 2 studies
Two phase 1 clinical trials of bevacizumab have been 
reported. In a phase 1 safety and pharmacokinetic study, 
bevacizumab was administered to 25 patients with refractory 
solid tumors at escalating doses ranging from 0.1 to 10 mg/kg 
(Gordon et al 2001) over 6 weeks. In a phase 1b trial, bevaci-
zumab, at a dose of 3 mg/kg, was administered in combina-
tion with chemotherapy to 12 patients with advanced cancer 
(Margolin et al 2001). Those trials showed that bevacizumab 
can be administered safely, without dose-limiting toxici-
ties, at doses up to 10 mg/kg, and that it can be combined 
with chemotherapy without apparent synergistic toxicity. 
All patients who completed 6–12 months of therapy in the 
phase 1/2 trials of bevacizumab were given the opportunity 
to participate in an ongoing extension study (Langmuir et al 
2002). Of 52 patients with advanced solid tumors, 28 received 
bevacizumab for 1 year or more. The dosage of bevacizumab 
ranged from 5 to 15 mg/kg every 2 or 3 weeks. The majority 
of patients treated for 1 year had an observation period off 
therapy up to 6 months, but were able to restart bevacizumab 
at progression. Sixteen patients progressed on or before the 
observation period and restarted bevacizumab. The median 
duration of treatment was 14 months (range 11–36 months) 
and, at the time of reporting these results, a median survival 
time had not been reached (range 17 months to   40 months, 
with 20 patients alive).
In a phase 1/2 dose-finding trial involving 75 women 
heavily pre-treated with MBC, patients were assigned to receive 
single-agent bevacizumab in escalating doses ranging from 
3 mg/kg to 20 mg/kg every other week (Cobleigh et al 2003). 
The majority of patients (83%) had inﬁ  ltrating ductal carcinoma, 
and 96% had received prior anthracycline- or taxane-based 
therapy for metastatic disease. An overall response rate (ORR) 
of 9.3% was reported, with 17% of patients maintaining 
stable disease or better after 5 months of therapy. Four patients 
continued therapy for at least 1 year without progression. 
Twenty-one of the 75 (28%) patients were HER2 positive and 
47 (63%) were HER2 negative. Twelve of the 75 patients (16%) 
completed the 6-month trial and received all 13 scheduled doses 
of  bevacizumab. The median number of doses of  bevacizumab 
administered was 6 and the median duration of treatment was 
70 days. Treatment was well tolerated, with hypertension and 
proteinuria the most commonly reported toxicities. A phase 2 trial 
of bevacizumab with vinorelbine examined patients with MBC. 
Key eligibility criteria included prior chemotherapy with 1 or 
2 regimens for MBC (including trastuzumab for HER2-positive 
disease) and disease progression within 1 year of adjuvant 
chemotherapy. Patients received treatment with bevacizumab 
at a dose of 10 mg/kg every 2 weeks and vinorelbine at a dose 
of 25 mg/m2/week (adjusted for neutrophil count) until either 
the disease progresses or they experience undue toxicity. That 
trial has observed 17 responses (1 complete and 16 partial) 
among 55 patients (31% [ORR]). Overall, bevacizumab with 
vinorelbine was well tolerated, and toxicity analyses indicate 
only minor occurrences of hypertension, proteinuria, and 
epistaxis and one instance of pericardial effusion. Side effects 
were consistent with the historic experience of the use of 
vinorelbine with neither bleeding nor thrombotic major events 
noted (Burstein et al 2002).
Phase 3 trials
These data supported the initiation of a phase 3 clinical trial 
that combined bevacizumab with capecitabine in patients 
previously treated with anthracyclines and/or taxanes. Miller 
and colleagues (Miller et al 2005) compared capecitabine 
with capecitabine plus bevacizumab (study AVF2119 g). Biologics: Targets & Therapy 2008:2(4) 815
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This randomized phase 3 trial enrolled 462 women with 
MBC who had progressed following prior treatment with 
both an anthracycline- and taxane-containing regimen, and 
at least 1 but no more than 2 prior treatments for their MBC. 
Patients with HER-2 positive disease were permitted to be 
enrolled if they had had prior trastuzumab therapy. Patients 
were treated with capecitabine 2500 mg/m2 twice daily for 
days 1–14 on a 21-day cycle, alone or in combination with 
bevacizumab 15 mg/kg IV every 3 weeks.
Though response rate was signiﬁ  cantly increased in 
patients treated with combined therapy (19.8% vs 9.1%; 
p = 0.001), there was no difference in progression-free 
survival (PFS), the primary endpoint of the study. Combina-
tion therapy was well tolerated and appeared safe, with no 
apparent increase in capecitabine-related toxicities. Again, 
hypertension and proteinuria were the predominant toxici-
ties, with no reported grade 4 events for either. The failure 
to achieve a statistically signiﬁ  cant improvement in PFS 
may have been due to the refractory patient population and 
overall low response rates, as well as the failure to identify 
the cohort of patients for whom the targeted agents would be 
more effective. Indeed, angiogenic pathways become more 
numerously redundant as breast cancer progresses, suggest-
ing that the optimal time for anti-VEGF therapies is earlier 
in the course of the disease (Relf et al 1997). This hypothesis 
led to a second phase 3 trial evaluating the incorporation of 
bevacizumab in the ﬁ  rst-line chemotherapy for MBC.
The study E2100 (Miller et al 2007) randomized 
722 women with locally recurrent or MBC (almost all 
HER2-negative) to receive either single-agentweekly pacli-
taxel (90 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) 
or the same dose/schedule of paclitaxel plus bevacizumab 
(10 mg/kg days 1 and 15). Paclitaxel plus bevacizumab 
signiﬁ  cantly prolonged progression-free survival as compared 
with paclitaxel alone (median, 11.8 vs 5.9 months; hazard ratio 
(HR) for progression, 0.60; p   0.001) and increased the objec-
tive response rate (36.9% vs 21.2%, p   0.001). Combined 
therapy increased the 1-year survival rate (81.2% vs 73.4%, 
p = 0.01); however, the median overall survival was similar 
in the group receiving combined therapy and in the group 
receiving paclitaxel alone (26.7 months and 25.2 months, 
respectively; HR, 0.88; p = 0.16). Grade 3 or 4 hypertension 
(14.8% vs 0.0%, p   0.001), proteinuria (3.6% vs 0.0%, 
p   0.001), headache (2.2% vs 0.0%, p = 0.008), and cere-
brovascular ischemia (1.9% vs 0.0%, p = 0.02) were more 
frequent in patients receiving paclitaxel plus bevacizumab. 
Infection was more common in patients receiving paclitaxel 
plus bevacizumab (9.3% vs 2.9%, p   0.001), but febrile 
neutropenia was uncommon ( 1% overall). The authors 
concluded that initial therapy paclitaxel plus bevacizumab 
prolongs PFS, but not overall survival (OS), as compared with 
paclitaxel alone in MBC. However, this beneﬁ  t in PFS a role 
for bevacizumab in the treatment of MBC, and provides the 
impetus for further studies to investigate and reﬁ  ne the use of 
this potentially powerful agent. The XCALIBr trial evaluated 
capecitabine/bevacizumab in the ﬁ  rst-line treatment of patients 
with MBC (Miller et al 2006). Median time to progression 
(TTP; N = 106) was 5.7 months (95% conﬁ  dence interval 
[CI], 4.9–8.4 months); patients with estrogen receptor-positive 
disease (n = 57) had a superior outcome, with a median TTP 
of 8.9 months (95% CI, 7.5–13.6 months), compared with 
4 months (95% CI, 3–4.9 months) in patients with estrogen 
receptor-negative disease. Furthermore, ORR was 38% 
(47% in the estrogen receptor–positive population and 27% 
in the estrogen receptor–negative population), and median 
OS was  16 months ( 16.6 months in patients with estro-
gen receptor–positive disease and  7.5 months in patients 
with estrogen receptor–negative disease). Capecitabine/
bevacizumab was well tolerated in this previously untreated 
population; the majority of AEs were mild or moderate. 
Thirteen percent of patients reported grade 3 palmar-plantar 
erythrodysesthesia, 10% reported grade 3 pain, and (in the 
ﬁ  rst phase of the study) 2% reported grade 4 pulmonary 
embolism.
The beneﬁ  t of adding bevacizumab to a taxane in the 
ﬁ  rst-line treatment of MBC has been conﬁ  rmed in another 
trial. Results from the AVADO study, reported at the 
American Society of Clinical Oncology 44th Annual Meeting 
(Miles et al 2008) showed a signiﬁ  cant improvement in 
PFS, echoing the results of the E2100 study. AVADO used 
docetaxel and had a placebo group. Moreover, the trial also 
used different bevacizumab doses: E2100 used 10 mg/kg; 
and AVADO compared a high dose of 15 mg/kg and a low 
dose of 7.5 mg/kg. After a median follow-up of 11 months, 
the AVADO trial showed a statistically signiﬁ  cant difference 
in PFS between women taking bevacizumab plus docetaxel 
and those taking docetaxel alone; stratiﬁ  ed HR was 0.69 
(p = 0.0035) for the low dose and 0.61 (p = 0.0001) for the 
high dose. In other words, the risk for disease progression 
was reduced by 21% with the low dose and by 29% with the 
high dose. The median TTP progression was 8 months with 
docetaxel alone, compared with 8.7 months with docetaxel 
plus low-dose bevacizumab, and 8.8 months with docetaxel 
plus high-dose bevacizumab. The ORR, a secondary end 
point, was 44% with docetaxel alone, 55% with low-dose bev-
acizumab (p = 0.0295), and 63% with high-dose bevacizumab Biologics: Targets & Therapy 2008:2(4) 816
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(p = 0.0001). At the median follow-up of 11 months, 80% of 
the patients were still alive. Treatment-related deaths were 
50 (21%) after docetaxel alone, 49 (20%) after low-dose 
bevacizumab, and 37 (15%) after high-dose bevacizumab, 
giving a 1-year survival of 73%, 78%, and 83%, respectively. 
A ﬁ  nal analysis of OS data is expected by April 2009.
Maximizing antiangiogenic activity 
of cytotoxic agents
Several chemotherapeutic agents used routinely in cancer 
treatment are known to exert antiangiogenic activity. Maximal 
antiangiogenic activity typically requires prolonged exposure 
to low drug concentrations, which is in direct contrast to the 
strategy of using maximum tolerated doses when optimal 
tumor cell kill is the goal (Bocci et al 2002; Colleoni et al 
2002; Kerbel et al 2004). Three reports (Kusaka et al 1994; 
Muramaki et al 2005; Higgins et al 2007) have conﬁ  rmed 
the importance of dose and schedule in preclinical models. 
In all three, the combination of low, frequent-dose chemo-
therapy plus an agent that speciﬁ  cally targets the endothelial 
cell compartment (TNP-470 and anti-VEGF-2) controlled 
tumor growth much more effectively than the cytotoxic 
agent alone. These studies suggest that activated endothelial 
cells could be more sensitive, or even selectively sensitive, 
to protracted low-dose chemotherapy compared with other 
types of normal cells, thus creating a potential therapeutic 
window. Thus so far, only a few clinical trials have tested 
antiangiogenic schedules of chemotherapy – the so-called 
“metronomic therapy” (Emmenegger et al 2007). A phase 2 
study (Colleoni et al 2002) of low-dose methotrexate (2.5 mg 
twice daily for 2 days each week) and cyclophosphamide 
(50 mg daily) in patients with previously treated MBC found 
an ORR rate of 19% (an additional 13% of patients were 
stable for 6 months or more). Serum VEGF levels decreased 
in all patients remaining on therapy for at least 2 months but 
did not correlate with response. The preclinical data suggest 
that metronomic chemotherapy will be more effective when 
combined with a second antiangiogenic agent. To test this 
hypothesis, Burstein et al (2005) enrolled 55 patients with 
MBC and no more than 1 prior chemotherapy regimen in a 
randomized phase 2 trial of metronomic cyclophosphamide 
(50 mg/day) and methotrexate (2.5 mg twice daily on days 
1 and 2 each week) alone or with bevacizumab (10 mg/kg 
every 2 weeks). ORR was 10% in the 21 patients treated 
with metronomic therapy alone and 29% in the 34 patients 
treated with metronomic chemotherapy plus bevacizumab. 
More recently, Dellapasqua et al reported the results of a 
phase 2 study with metronomic cyclophosphamide (50 mg 
daily) and capecitabine (500 mg twice daily) combined with 
bevacizumab(10 mg/kg every 2 weeks) in MBC (Dellapasqua 
et al 2008).
In 46 assessable patients, they observed one complete 
response (CR; 2%), 21 partial responses (PR; 46%), 19 patients 
(41%) with stable disease (SD), and 5 patients (11%) with 
progressive disease, for an ORR of 48% (95% CI, 33%–63%). 
Additional long-term disease stabilization (SD   24 weeks) 
occurred in eight patients, for an overall clinical beneﬁ  t 
(CR + PR + SD   24 weeks) of 68% (95% CI, 51%–81%). 
Median TTP was 42 weeks (95% CI, 26–72 weeks). 
Toxicity was generally mild. Grade 3 or 4 non-hematologic 
adverse effects included hypertension, transaminitis, and 
nausea/vomiting. Circulating endothelial cells (CECs) were 
correlated with ORR (p   0.02), clinical beneﬁ  t (p   0.01), 
and improved PFS (p   0.04). They concluded that treatment 
with metronomic capecitabine and cyclophosphamide in com-
bination with bevacizumab was effective in MBC and was 
minimally toxic. The number of baseline CECs signiﬁ  cantly 
correlated with response and outcome, supporting further 
studies on this surrogate marker for patient selection for 
antiangiogenic treatments.
Safety and toxicity data 
with bevacizumab
Bevacizumab appeared safe and manageable in patients with 
MBC, with minimal additional toxicity seen when combined 
with other agents. However, the addition of bevacizumab 
increased the incidence of hypertension and proteinuria. 
Proteinuria is virtually always asymptomatic with similar 
rates reported in two phase 3 trials (only 1% reported grade 4 
events). Mild proteinuria can be followed simply by periodic 
urinalysis, with concurrent monitoring for the development 
of hypertension. Higher levels of proteinuria should prompt 
24-hour urine collection, and bevacizumab should be with-
held for protein level  2 g/24 hours. The agent can be 
resumed with close observation when urine protein level falls 
below 2 g/24 hours. In E2100, grade 3 hypertension occurred 
in 15% of patients in the combination arm, compared with 
2% in the single-agent paclitaxel arm. Similar rates were 
reported in the capecitabine trial (17.9% vs 0.5%). There 
was no reported grade 4 hypertension in the capecitabine trial 
and  1% reported in E2100. Hypertension can usually be 
managed with the addition of oral agents without the need for 
dose-reduction or discontinuation of bevacizumab; transient 
interruption of bevacizumab therapy may be required to 
allow adequate blood pressure control in rare patients. There 
is no consensus as to the ideal oral agent for the treatment Biologics: Targets & Therapy 2008:2(4) 817
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of bevacizumab-induced hypertension. Some authors have 
suggested a preference for calcium-channel antagonists, 
while others favor angiotensin-converting-enzyme inhibi-
tors, particularly in patients with coexisting proteinuria. 
Whether or not hypertension develops, close monitoring of 
blood pressure and urine protein levels is mandatory during 
bevacizumab treatment. Cumulative experience from mul-
tiple phase 3 trials, including those in patients with MBC, 
conﬁ  rms this experience. Additional severe adverse events 
have been reported with bevacizumab: hypertension, includ-
ing hypertensive crisis; proteinuria, including nephritic syn-
drome; thrombosis (venous and arterial), including cerebral 
and myocardial infarction, transient ischemic attacks, and 
deep venous thrombosis; bleeding and hemorrage; impaired 
wound healing; gastrointestinal perforation; congestive 
heart failure (seen only in patients receiving anthracyclines 
and/or left chest-wall irradiation). These events are exceed-
ingly rare, but do warrant consideration in selected patients 
for whom bevacizumab is planned (Midgley et al 2005). In 
breast cancer studies there has been some concern about 
the development of congestive heart failure (CHF), with an 
apparent, though non-signiﬁ  cant, increase in events reported 
in the initial MBC with capecitabine study (Table 1). Current 
experience suggests that prior or concurrent anthracycline 
therapy or left-chest wall irradiation are risk factors for CHF 
during bevacizumab therapy. It is hoped that an ongoing trial 
in the adjuvant setting (E2104) will clarify the impact of 
bevacizumab on cardiac function (Miller et al 2007).
There has been some concern about risk for hemorrhage 
with the use of bevacizumab, particularly the potential for 
central nervous system (CNS) bleeds. While E2100 reported 
similar rates of minor mucosal bleeds for both treatment arms, 
the trial design intentionally excluded patients with CNS 
metastasis at the time of study accrual, given the unknown 
potential risk for hemorrhage at these sites. Because the safety 
of bevacizumab in patients with CNS metastasis remains 
unknown, the drug is best avoided in this setting for now. 
Clinicians should perform CNS imaging prior to therapy 
with bevacizumab to rule out occult metastasis (Genentech 
Inc.), and withhold the drug if detected. Venous and arterial 
thrombotic events also have been reported in other trials, 
including cerebral and myocardial infarction and pulmonary 
embolism. Clinicians should consider avoiding bevacizumab 
in patients with a history of prior thrombotic events and in 
patients receiving systemic anticoagulation, because the 
combination has not been studied in MBC. Patients with 
MBC on prophylactic aspirin (81–325 mg daily) have been 
safely treated with bevacizumab with no signiﬁ  cant increased 
risk for bleeding.
Finally, a recent work supports an association between 
VEGF genotype and median OS as well as grade 3 or 
4 hypertension when using bevacizumab in MBC. The 
VEGF-2578 AA genotype was associated with a superior 
median overall survival (OS) in the combination arm 
when compared with the alternative genotypes combined 
(HR, 0.58; 95% CI, 0.36–0.93; p = 0.023). The VEGF-1154 
A allele also demonstrated a superior median OS with an 
additive effect of each active allele in the combination arm 
but not the control arm (HR, 0.62; 95% CI, 0.46–0.83; 
p = 0.001). Two additional genotypes, VEGF-634 CC and 
Table 1 Reported incidence of congestive heart failure with bevacizumab
Study/Regimen Observed incidence of congestive 
heart failure
Reference
Bevacizumab monotherapy in breast 
cancer
2/75 patients (2.7%) – both received 
prior doxorubicin
Cobleigh et al 2003
Capecitabine ± bevacizumab in breast 
cancer
2 (0.9%) vs 7 (3.1%) Miller et al 2006
E2100 – bevacizumab + paclitaxel in breast 
cancer
Preliminary data showing 1/342 (0.3%) Miller et al 2007
AML
(1-beta-d-arabinofuranosylcytosine, 
mitoxantrone + bevacizumab)
6% incidence of CHF Karp et al 2004
Neoadjuvant AT + bevacizumab 
inﬂ  ammatory breast
2/21 (9.5%) Wedam et al 2006
Doxorubicin + bevacizumab metastatic 
sarcomas
2/17 (11.8%) CHF + 4/17 (23.5%) 
decrease LVEF
D’Adamo et al 2005
Abbreviations:   AML, acute myeloid leukemia;   AT, doxorubicin and docetaxel;  CHF, congestive heart failure;  LVEF, left-ventricular ejection fraction.Biologics: Targets & Therapy 2008:2(4) 818
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VEGF-1498 TT, were associated with signiﬁ  cantly less 
grade 3 or 4 hypertension in the combination arm when 
compared with the alternate genotypes combined (p = 0.005 
and p = 0.022, respectively) (Schneider et al 2008). This is a 
ﬁ  rst report that needs to be further investigated to improve 
the use and safety of this drug.
Ongoing trials in HER2-negative 
breast cancer patients
Because antiangiogenic therapy has the potential to improve 
the clinical outcome in patients with MBC, there is a need to 
optimize its use, particularly early in the course of metastatic 
disease. 
The ongoing RiBBON studies are large, multicenter, 
randomized, placebo-controlled phase 3 trials that are evaluat-
ing the efﬁ  cacy and safety of bevacizumab in combination 
with standard-of-care chemotherapy regimens in patients 
with previously untreated (RiBBON 1) or previously treated 
(RiBBON 2) MBC (O’Shaughnessy et al 2008). Because 
investigators are given the choice of which chemotherapy 
regimen to use, the RiBBON trials might provide data to 
support the use of bevacizumab in combination with various 
standard-of-care chemotherapy agents, including capecitabine. 
The capecitabine arm in this study is adequately powered for 
a statistically signiﬁ  cant difference in capecitabine versus 
capecitabine/bevacizumab to be demonstrated. Another 
unique feature is that RiBBON 2 is a purely second-line study, 
in contrast with the AVF2119g trial, in which approximately 
40% of patients had been treated with  2 chemotherapy 
regimens for MBC. Besides the use of bevacizumab in the 
metastatic setting, it has been hypothesized that the greater 
beneﬁ  t could be obtained when used in earlier stages. The 
progression of breast cancer is accompanied by the production 
of a wide array of proangiogenic growth factors that promote 
and support tumor growth. When tumors are small they 
secrete VEGF, which acts as a paracrine factor to induce 
endothelial cell proliferation and blood vessel formation, 
mediating tumor progression. As the tumor develops further, 
additional factors are also secreted. This evidence suggests 
that the inhibition of VEGF may be more beneﬁ  cial in earlier 
stages, as neoadjuvant or adjuvant treatment. 
There are many trials, planned and ongoing, exploring 
bevacizumab in the neoadjuvant setting. An ongoing, phase 
2 trial of bevacizumab in combination with docetaxel in the 
neoadjuvant setting (AVF2307s) (Cortés-Funes 2007) is 
being conducted in patients with locally unresectable breast 
cancer with or without metastasis. Patients receive bevaci-
zumab 10 mg/kg every 2 weeks and docetaxel 35 mg/m2 
weekly for the ﬁ  rst 6 weeks of an 8-week cycle. After 
2 cycles, patients with stable disease or response, undergo 
R
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T
E
R
Arm A: ddBAC>BT>B
Arm B: ddAC>BT>B
Doxorubicin 60 mg/m2 plus
cyclophosphamide 600 mg/m2
every 14 days for 4 cycles
Paclitaxel 175 mg/m2
Bevacizumab 10 mg/kg 
every 14 days
Paclitaxel 175 mg/m2
Bevacizumab10 mg/kg
every 14 days 
Bevacizumab10
mg/kg every 14
days for 5 cycles
Bevacizumab10
mg/kg every 14
days for 9 cycles 
Key
Arm A: dd (dose dense) B (bevacizumab) A (doxorubicin) B 
(bevacizumab) T (paclitaxel) > B (bevacizumab) 
Arm B: dd (dose dense) A (doxorubicin) C (cyclophosphamide) 
(paclitaxel) > B (bevacizumab)
Doxorubicin 60 mg/m2 plus
cyclophosphamide 600 mg/m2
Bevacizumab10 mg/kg every 14 
days for 4 cycles
Figure 1 ECOG Study 2104.Biologics: Targets & Therapy 2008:2(4) 819
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surgery and radiotherapy, followed by further chemotherapy 
(not containing bevacizumab). The study objectives are to 
evaluate the efﬁ  cacy and safety of neoadjuvant bevacizumab 
with docetaxel in breast cancer patients. 
TORI-B-02 (http://clinicaltrials.gov/ct2/show/NCT002
03372?term=TORI+B02&rank=1) is a phase 2 neoadjuvant 
trial currently being conducted at the University of California, 
Los Angeles. A total of 90 patients are being enrolled into 
4 different treatment arms, in order to compare 2 different 
bevacizumab doses with placebo: Arm 1: bevacizumab 
7.5 mg/kg, followed by 6 cycles of bevacizumab 7.5 mg/kg 
in combination with TAC (docetaxel, doxorubicin and cyclo-
phosphamide) every 3 weeks; Arm 2: placebo 7.5 mg/kg, fol-
lowed by 6 cycles of placebo 7.5 mg/kg in combination with 
TAC every 3 weeks; Arm 3: bevacizumab 15 mg/kg, followed 
by 6 cycles of bevacizumab 15 mg/kg in combination with 
TAC every 3 weeks; and Arm 4: placebo 15 mg/kg, followed 
by 6 cycles of placebo 15 mg/kg in combination with TAC 
every 3 weeks. Then, 28 to 42 days after receiving chemo-
therapy, patients eligible for surgery will undergo resection. 
After either receiving surgery or completing chemotherapy, 
patients in Arms 1 and 3 will receive bevacizumab at their 
previous dose until disease progression. Patients in Arms 2 and 
4 will not receive further therapy before disease progression. 
The primary objectives of the TORI-B-02 trial are to evaluate 
the safety and toxicity of bevacizumab given as preoperative 
therapy to patients with stage II/III breast cancer in combina-
tion with the TAC regimen. Analysis of changes in HIF-1α 
levels will also be carried out, in order to compare tumor 
angiogenesis in patients given bevacizumab and placebo. 
Other trial objectives include investigation of the clinical 
beneﬁ  t of adding bevacizumab to TAC in the neoadjuvant 
setting. Parameters to be evaluated are the clinical objective 
response rate (complete response plus partial response), patho-
logic complete response rate and rate of breast-conserving 
surgery. As wound-healing complications have previously 
been reported in bevacizumab clinical trials, the effect of 
bevacizumab on post-surgical wound-healing will also be 
investigated as well as the rate of cardiac heart failure.
Another ongoing study in the adjuvant setting is the 
BEATRICE study. This 2-arm open-label study will evalu-
ate the efﬁ  cacy and safety of the addition of bevacizumab 
to standard adjuvant therapy in patients with triple negative 
breast cancer. Patients will be randomized to receive either 
standard chemotherapy (anthracycline ± taxane or taxane 
only), or standard chemotherapy given concurrently with 
1 year of bevacizumab (5 mg/kg/week dosing equivalent iv). 
The anticipated time on study treatment is 3 to 12 months. 
Target sample size is 2530. The most successful use of 
antiangiogenic therapy has been predicted to be in the adjuvant 
treatment, and there is a clear biologic basis and rationale for 
exploring bevacizumab in this clinical setting. A large propor-
tion of patients with breast cancer have been reported to have 
primary tumors that over express VEGF, and over expression 
of VEGF is associated with increased rates of relapse. 
The trials planned with bevacizumab in the adjuvant setting 
will conﬁ  rm the efﬁ  cacy of adding an antiangiogenic therapy 
to standard combinations. The ECOG trial E2104 (Figure 1) 
(Miller et al 2007) is a 2-armed, non-randomized pilot study 
to evaluate the efﬁ  cacy of bevacizumab as an adjuvant therapy 
in patients with HER2-negative, lymph node-positive early 
breast cancer. Accrual onto each arm of the trial was carried 
out sequentially in cohorts of 106 patients, beginning with 
arm A. Patients in arm A of the trial received 4 cycles of 
doxorubicin (60 mg/m2), cyclophosphamide (600 mg/m2) and 
bevacizumab (10 mg/kg) every 2 weeks, followed by 4 cycles 
of paclitaxel (175 mg/m2) and bevacizumab (10 mg/kg) every 
2 weeks. Patients then received bevacizumab (10 mg/kg) 
alone for 18 2-week cycles. Patients in arm B of the trial 
received 4 cycles of doxorubicin (60 mg/m2) and cyclophos-
phamide (600 mg/m2) every 2 weeks, followed by 4 cycles of 
paclitaxel (175 mg/m2) and bevacizumab (10 mg/kg) every 
2 weeks. This was followed by bevacizumab (10 mg/kg) alone 
for 22 2-week cycles. Growth factor support with granulocyte 
colony stimulating factor was used during chemotherapy, but 
not required with single-agent bevacizumab. The primary 
endpoint is safety concerning the incidence of clinically 
apparent cardiac dysfunction. Preliminary safety data indicate 
that this combination is feasible, with cardiac toxicity within 
acceptable limits in both trial arms.
A planned 4950 patients will participate in the ECOG study 
E5103 (ecog.dfci.harvard.edu/general/videos/etpages/e5103.
html), a randomized, phase 3 trial to evaluate the efﬁ  cacy and 
safety of bevacizumab as an adjuvant therapy in combination 
with chemotherapy. Eligible patients have ER-negative or 
high-risk estrogen-receptor positive, HER2-negative early 
breast cancer. Patients in arm A of the trial will receive 4 cycles 
of doxorubicin (60 mg/m2), cyclophosphamide (600 mg/m2) 
and placebo every 2 or 3 weeks (at the discretion of the 
investigator), followed by 12 cycles of weekly paclitaxel 
(80 mg/m2) plus placebo. Patients in arm B of the trial will 
receive 4 cycles of doxorubicin (60 mg/m2), cyclophosphamide 
(600 mg/m2) and bevacizumab (15 mg/kg) every 2 or 3 weeks, 
followed by 12 cycles of weekly paclitaxel (80 mg/m2) in 
combination with 4 cycles of bevacizumab (15 mg/kg) every 
3 weeks. Patients in arm C of the trial will receive doxorubicin, Biologics: Targets & Therapy 2008:2(4) 820
Lorusso
cyclophosphamide and bevacizumab followed by weekly 
paclitaxel and bevacizumab as in arm B, with an additional 
ten 3-weekly cycles of bevacizumab (15 mg/kg). The primary 
trial endpoint is disease-free survival.
Conclusion
Angiogenesis has a clear and deﬁ  nite role in breast cancer 
progression and metastasis, making anti-VEGF therapies an 
attractive option for proceding with trials of efﬁ  cacy. Beva-
cizumab is an effective adjunct in the treatment of MBC, 
particularly when combined with paclitaxel in the ﬁ  rst-line 
setting. The drug is well tolerated, with minimal additional 
toxicity, but does require close monitoring of blood pressure 
and urine protein levels throughout treatment. Beyond the 
ﬁ  rst-line setting, bevacizumab may be less beneﬁ  cial, because 
tumors seemingly alter their angiogenesis pathways, relying 
less heavily on VEGF as they progress. Future research will 
seek to combine anti-VEGF agents in the neoadjuvant or 
adjuvant setting, where even more potential may exist for 
patients with breast cancer. The potential to use multiple 
targeted agents (eg, bevacizumab with trastuzumab) is also 
worthy of future consideration, and studies are currently 
exploring these strategies as well.
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